Ecuador presented new clinical trial regulations in 2025 with PAHO technical assistance — the framework has been presented but is not necessarily fully in force yet — and continues to follow the Declaration of Helsinki, CIOMS guidelines, and ISO 14155. ARCSA (National Agency for Regulation, Control and Sanitary Surveillance) authorizes clinical trials and classifies medical devices into classes I, IIa, IIb, and III. With CEISH ethics review and bioaccess®'s coordination, sponsors generate FDA-submissible data at ~30% lower cost than US/EU programs.
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO — the framework has been presented but is not necessarily fully in force yet. It aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155, giving sponsors an internationally-recognizable pathway for medical research.
ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) — a decentralized Ministry of Health agency — is the national authority that authorizes clinical trials and classifies medical devices into classes I, IIa, IIb, and III. Studies must also be approved by a Human Research Ethics Committee (CEISH) before enrollment can begin.
bioaccess® coordinates ARCSA authorization, CEISH ethics review, site qualification, and monitoring so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program. Ecuador fits well within multi-country LATAM programs.
ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) is a decentralized agency of Ecuador's Ministry of Health and serves as the national authority that authorizes clinical trials. ARCSA classifies medical devices into classes I, IIa, IIb, and III, providing a risk-proportionate framework for MedTech sponsors. bioaccess® prepares complete ARCSA dossiers.
Every clinical study in Ecuador must be approved by a Human Research Ethics Committee (CEISH — Comité de Ética de Investigación en Seres Humanos) before enrollment can begin. Ethics review follows the Declaration of Helsinki, CIOMS guidelines, and GCP. bioaccess® coordinates CEISH submissions and manages committee questions.
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO. The framework has been presented but is not necessarily fully in force yet; it aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155. bioaccess® stays current on the evolving framework and applies it to each program.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Ecuador for IDE submissions and marketing applications when studies are conducted under ISO 14155 with proper ARCSA authorization and CEISH ethics approval. bioaccess® designs every protocol for FDA submission from day one.
| Metric | Ecuador 🇪🇨 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory authority | ARCSA (decentralized MoH agency) | FDA | EMA / national CAs |
| Ethics review | Human Research Ethics Committee (CEISH) | Local IRBs | Per-country ECs |
| Regulatory framework | 2025 (PAHO-supported, being implemented) | 21 CFR / ISO 14155 | EU CTR / MDR |
| Standards followed | Helsinki + CIOMS + ISO 14155 | 21 CFR / ISO 14155 | ISO 14155 |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) — a decentralized Ministry of Health agency — is the national authority that authorizes clinical trials in Ecuador.
ARCSA classifies medical devices into classes I, IIa, IIb, and III, providing a risk-proportionate framework aligned with international practice.
Studies must be approved by a Human Research Ethics Committee (CEISH — Comité de Ética de Investigación en Seres Humanos) before enrollment can begin, following the Declaration of Helsinki, CIOMS guidelines, and ISO 14155.
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO. The framework has been presented but is not necessarily fully in force yet; it aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from Ecuador when studies are conducted under ISO 14155 with proper ARCSA authorization and CEISH ethics approval. bioaccess® designs protocols for FDA submission from the start.
Ecuador programs typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
All countries we serve · Contact bioaccess® · First-in-Human CRO